Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR5F9A
|
|||
| Drug Name |
CM24
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Company |
Purple
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Biliary glycoprotein 1 (CEACAM1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04731467) A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Purple | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.